Pepcid AC garners leading share of antacid market since June launch -- J&J/Merck.
PEPCID AC SHARE OF HEARTBURN CATEGORY PEGGED AT OVER 20% by Johnson & Johnson/Merck. The company said in a Sept. 5 legal document that Pepcid AC has captured more than 20% of the $800 mil. "heartburn relief" category in "recent weeks." J&J/Merck launched the Rx-to-OTC switch H2 antagonist in June ("The Tan Sheet" June 12, p. 3).
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’